AR034249A1 - USE OF QUINOLINE DERIVATIVES AS ALFA-2 ANTAGONISTS; COMPOUNDS DERIVED FROM QUINOLINA AND ITS COMPOSITIONS - Google Patents
USE OF QUINOLINE DERIVATIVES AS ALFA-2 ANTAGONISTS; COMPOUNDS DERIVED FROM QUINOLINA AND ITS COMPOSITIONSInfo
- Publication number
- AR034249A1 AR034249A1 ARP010100993A ARP010100993A AR034249A1 AR 034249 A1 AR034249 A1 AR 034249A1 AR P010100993 A ARP010100993 A AR P010100993A AR P010100993 A ARP010100993 A AR P010100993A AR 034249 A1 AR034249 A1 AR 034249A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- mono
- alkoxy
- halogen
- alkylamino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
El uso de compuestos derivados de quinolina de la fórmula (1), en donde: R1 es H ó alquilo C1-6; cada R2 es independientemente OH, halógeno, alquilo C1-6, alquenilo C2-6, alcoxi C1-6, haloalquilo C1-6, NO2, NH2, mono- ó di-alquilamino C1-6, alquil C1-6-S- ó hidroxialquilo C1-6; A es un anillo de benceno o cicloalquilo C5-7; cuando A es un anillo de benceno cada R3 es independientemente OH, halógeno, alquilo C1-6, alquenilo C2-6, alcoxi C1-6, haloalquilo C1-6, NO2, NH2, mono- o di-alquilamino C1-6, alquil C1-6-CO-, mono- o di-alquilcarbamoilo C1-6, alquil C1-6-S-, hidroxialquilo C1-6 ó NH2-CO-; cuando A es cicloalquilo C5-7, cada R3 es independientemente OH, halógeno, alquilo C1-6, alcoxi C1-6, mono- o di-alquilamino C1-6 ó hidroxialquilo C1-6; R4 y R5 forman, junto con el átomo de nitrógeno en donde están unidos, un resto de fórmula (2), en donde X es O ó =NR6; R6 es H, OH, NH2, alquilo C1-6, alquenilo C2-6, CN-alquilo C1-6, alcoxi C1-6-CO-alquil C1-6, alquil C1-6-CO-, NH2-CO-, mono- o di-alquilcarbamoilo C1-6, hidroxialquilo C1-6, cicloalquilo C3-6, fenilo, naftilo, bencilo, en donde el fenilo, naftilo o bencilo está opcionalmente sustituido con 1 a 3 sustituyentes cada uno seleccionado independientemente de OH, halógeno, NO2, NH2, alquilo C1-6, alcoxi C1-6, mono- o di-alquilamino C1-6 y haloalquilo C1-6; o R4 y R5 forman, junto con el átomo de nitrógeno en donde están unidos, un resto de fórmula (3) en donde n es 1 ó 2; R6 es como se define anteriormente; y r es 0 a 3; o R4 y R5 forman, junto con el átomo de nitrógeno en donde están unidos, 1-imidazolilo, 1-imidazolinilo ó 1-triazolilo, cada uno de los cuales puede estar opcionalmente sustituido con 1 a 3 sustituyentes, R7, cada uno seleccionado independientemente de alquilo C1-6 y NH2; o uno de R4 y R5 es -SO2R8 y el otro de R4 y R5 es H o alquilo C1-6; R8 se selecciona independientemente a partir de alquilo C1-6, fenilo, naftilo y bencilo, en donde el fenilo, naftilo o bencilo está opcionalmente sustituido con 1 a 3 sustituyentes R9, cada uno seleccionado independientemente a partir de OH, halógeno, NO2, NH2, alquilo C1-6, alcoxi C1-6, mono- o di-alquilamino C1-6; Ra y Rb son independientemente H, OH, halógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, haloalquilo C1-6, NO2, NH2, mono- o di-alquilamino C1-6, alquil C1-6-S- ó CN; o Ra y Rb forman, junto con los átomos del anillo de carbono en donde están unidos, un anillo de benceno condensado opcionalmente sustituido con 1 a 3 sustituyentes R'3 cada uno seleccionado independientemente a partir de OH, halógeno, alquilo C1-6, alquenilo C2-6, alcoxi C1-6, haloalquilo C1-6, NO2, NH2, mono- o di-alqulamino C1-6, alquil C1-6-CO-, mono- o di-alquilcarbamoilo C1-6, y alquil C1-6-S-, hidroxialquilo C1-6 o NH2-CO-; o Ra y Rb forman, junto con los átomos del anillo de carbono en donde están unidos, un anillo carboxílico de 5 a 7 miembros, condensado opcionalmente sustituido con 1 a 4 sustituyentes R10 cada uno seleccionado independientemente a partir de OH, halógeno, alquilo C1-6, alcoxi C1-6, mono- o di-alquilamino C1-6, e hidroxialquilo C1-6; o Ra y Rb forman, junto con los átomos del anillo de carbón en donde están unidos, un anillo de biciclo[2.2.1]-heptano condensado opcionalmente sustituido con 1 a 4 sustituyentes cada uno seleccionado independientemente a partir de OH, halógeno, alquilo C1-6, y alcoxi C1-6; o Ra y Rb forman, junto con los átomos del anillo de carbono en donde están unidos, un anillo heterocíclico de 5 a 6 miembros, condensado con un heteroátomo de anillo =NR11, anillo heterocíclico que está opcionalmente sustituido con 1 a 3 sustituyentes R10 como se define anteriormente; R11 es H o alquilo C1-6, o R11 es fenilo opcionalmente sustituido con 1 a 3 sustituyentes R12 cada uno seleccionado independientemente a partir de OH, halógeno, NO2, NH2, alquilo C1-6, alcoxi C1-6 y mono- o di-alquilamino C1-6; m es 0 a 3; y t es 0 a 3; o sales y ésteres farmacéuticamente aceptables de los mismos, en la fabricación de un medicamento para el tratamiento de enfermedades o condiciones donde se indica que son efectivos los antagonistas alfa-2. Preferiblemente en el tratamiento de trastornos del sistema nervioso central. Compuestos derivados de quinolina y composiciones farmacéuticas que los comprenden.The use of quinoline-derived compounds of the formula (1), wherein: R1 is H or C1-6 alkyl; each R2 is independently OH, halogen, C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, C1-6 haloalkyl, NO2, NH2, mono- or di- C1-6 alkylamino, C1-6-S-alkyl C1-6 hydroxyalkyl; A is a benzene or C5-7 cycloalkyl ring; when A is a benzene ring each R3 is independently OH, halogen, C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, C1-6 haloalkyl, NO2, NH2, mono- or di- C1-6 alkylamino, alkyl C1-6-CO-, mono- or di-C1-6 alkylcarbamoyl, C1-6-S- alkyl, C1-6 hydroxyalkyl or NH2-CO-; when A is C5-7 cycloalkyl, each R3 is independently OH, halogen, C1-6 alkyl, C1-6 alkoxy, mono- or di- C1-6 alkylamino or C1-6 hydroxyalkyl; R4 and R5 form, together with the nitrogen atom where they are attached, a remainder of formula (2), where X is O or = NR6; R6 is H, OH, NH2, C1-6 alkyl, C2-6 alkenyl, CN-C1-6 alkyl, C1-6-alkoxy-C1-6 alkyl, C1-6-CO- alkyl, NH2-CO-, mono- or di-C 1-6 alkylcarbamoyl, C 1-6 hydroxyalkyl, C 3-6 cycloalkyl, phenyl, naphthyl, benzyl, wherein phenyl, naphthyl or benzyl is optionally substituted with 1 to 3 substituents each independently selected from OH, halogen , NO2, NH2, C1-6 alkyl, C1-6 alkoxy, mono- or di- C1-6 alkylamino and C1-6 haloalkyl; or R4 and R5 form, together with the nitrogen atom where they are attached, a residue of formula (3) where n is 1 or 2; R6 is as defined above; and r is 0 to 3; or R4 and R5 form, together with the nitrogen atom where they are attached, 1-imidazolyl, 1-imidazolinyl or 1-triazolyl, each of which may be optionally substituted with 1 to 3 substituents, R7, each independently selected C1-6 alkyl and NH2; or one of R4 and R5 is -SO2R8 and the other of R4 and R5 is H or C1-6 alkyl; R8 is independently selected from C1-6 alkyl, phenyl, naphthyl and benzyl, wherein the phenyl, naphthyl or benzyl is optionally substituted with 1 to 3 R9 substituents, each independently selected from OH, halogen, NO2, NH2 , C1-6 alkyl, C1-6 alkoxy, mono- or di- C1-6 alkylamino; Ra and Rb are independently H, OH, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkyl, NO 2, NH 2, mono- or di- C 1-6 alkylamino, C1-6-S- or CN alkyl; or Ra and Rb together with the carbon ring atoms where they are attached, a condensed benzene ring optionally substituted with 1 to 3 R'3 substituents each independently selected from OH, halogen, C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, C1-6 haloalkyl, NO2, NH2, mono- or di- C1-6 alkylamino, C1-6-CO- alkyl, mono- or di-C1-6 alkylcarbamoyl, and C1-alkyl -6-S-, C1-6 hydroxyalkyl or NH2-CO-; or Ra and Rb together with the carbon ring atoms where they are attached, a 5 to 7 membered carboxylic ring, optionally substituted with 1 to 4 R10 substituents each independently selected from OH, halogen, C1 alkyl -6, C1-6 alkoxy, mono- or di- C1-6 alkylamino, and C1-6 hydroxyalkyl; or Ra and Rb together with the carbon ring atoms where they are attached, a condensed bicyclo [2.2.1] -heptane ring optionally substituted with 1 to 4 substituents each independently selected from OH, halogen, alkyl C1-6, and C1-6 alkoxy; or Ra and Rb form, together with the carbon ring atoms where they are attached, a 5- to 6-membered heterocyclic ring, fused to a ring heteroatom = NR11, heterocyclic ring that is optionally substituted with 1 to 3 R10 substituents as defined above; R11 is H or C1-6 alkyl, or R11 is phenyl optionally substituted with 1 to 3 R12 substituents each independently selected from OH, halogen, NO2, NH2, C1-6 alkyl, C1-6 alkoxy and mono- or di -C 1-6 alkylamino; m is 0 to 3; and t is 0 to 3; or pharmaceutically acceptable salts and esters thereof, in the manufacture of a medicament for the treatment of diseases or conditions where alpha-2 antagonists are indicated to be effective. Preferably in the treatment of disorders of the central nervous system. Quinoline-derived compounds and pharmaceutical compositions that comprise them.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20000480A FI20000480A0 (en) | 2000-03-01 | 2000-03-01 | Quinoline and naphthalene derivatives as alpha-2 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
AR034249A1 true AR034249A1 (en) | 2004-02-18 |
Family
ID=8557801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010100993A AR034249A1 (en) | 2000-03-01 | 2001-03-01 | USE OF QUINOLINE DERIVATIVES AS ALFA-2 ANTAGONISTS; COMPOUNDS DERIVED FROM QUINOLINA AND ITS COMPOSITIONS |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1263733A2 (en) |
JP (1) | JP2003525274A (en) |
KR (1) | KR20020089372A (en) |
CN (1) | CN1468224A (en) |
AR (1) | AR034249A1 (en) |
AU (1) | AU2001239331A1 (en) |
BR (1) | BR0108816A (en) |
CA (1) | CA2400657A1 (en) |
CZ (1) | CZ20022880A3 (en) |
EE (1) | EE200200490A (en) |
FI (1) | FI20000480A0 (en) |
HU (1) | HUP0204458A3 (en) |
IL (1) | IL151093A0 (en) |
MX (1) | MXPA02008402A (en) |
NO (1) | NO20024159D0 (en) |
PE (1) | PE20011084A1 (en) |
PL (1) | PL357874A1 (en) |
RU (1) | RU2002125944A (en) |
SK (1) | SK12332002A3 (en) |
WO (1) | WO2001064645A2 (en) |
ZA (1) | ZA200206956B (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162859A0 (en) * | 2002-02-05 | 2005-11-20 | Novo Nordisk As | Novel aryl-and heteroarylpiperazines |
CA2480266C (en) * | 2002-04-03 | 2011-07-12 | Orion Corporation | Use of an alpha2-adrenoreceptor antagonist for cns-related diseases |
WO2003082866A1 (en) | 2002-04-03 | 2003-10-09 | Orion Corporation | Polycyclic compounds as potent alpha2-adrenoceptor antagonists |
WO2003093240A1 (en) * | 2002-04-30 | 2003-11-13 | Yungjin Pharmaceutical Co., Ltd. | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same |
WO2004067513A1 (en) * | 2003-01-27 | 2004-08-12 | Oy Juvantia Pharma Ltd | Antagonists for alpha-2 adrenoceptors |
AU2006264966B2 (en) | 2005-07-04 | 2013-02-21 | High Point Pharmaceuticals, Llc | Histamine H3 receptor antagonists |
WO2007053436A1 (en) | 2005-10-31 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor |
EP1968961A2 (en) * | 2005-12-21 | 2008-09-17 | Decode Genetics EHF | Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation |
CA2649707A1 (en) * | 2006-05-22 | 2007-11-29 | Janssen Pharmaceutica N.V. | Substituted pyrazinone derivatives for use as a medicine |
EP2038256A1 (en) | 2006-05-23 | 2009-03-25 | TransTech Pharma, Inc | 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ']-bipyridine and its use as a medicament |
CA2659570C (en) | 2006-05-29 | 2015-10-06 | High Point Pharmaceuticals, Llc | 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
TWI457122B (en) | 2007-07-20 | 2014-10-21 | Orion Corp | 2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases |
WO2010042473A1 (en) | 2008-10-07 | 2010-04-15 | Schering Corporation | Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators |
TW201024282A (en) | 2008-11-20 | 2010-07-01 | Orion Corp | New pharmaceutical compounds |
JP2013513588A (en) * | 2009-12-11 | 2013-04-22 | ジーンコード エーエス | Method for facilitating survival of neural cells using mimic or RET signaling pathway activators of GDNF family ligand (GFL) |
CN103524413B (en) * | 2012-07-04 | 2016-04-20 | 江苏先声药物研究有限公司 | hydrogenated acridine derivative and application thereof |
JOP20200052A1 (en) * | 2013-12-19 | 2017-06-16 | Bayer Pharma AG | Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists |
WO2015153535A1 (en) | 2014-03-31 | 2015-10-08 | MiRx Pharmaceuticals, LLC | Novel hdmx inhibitors and their use for cancer treatment |
WO2016135137A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135138A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135140A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135139A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer |
CN107337641B (en) * | 2017-07-01 | 2020-04-28 | 广东医科大学 | 4-flexible amino-2-arylvinyl quinoline derivative and preparation method and application thereof |
WO2023038876A1 (en) * | 2021-09-07 | 2023-03-16 | Gismo Therapeutics, Inc. | Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interactions with glycosaminoglycans, methods of treatment, and use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
-
2000
- 2000-03-01 FI FI20000480A patent/FI20000480A0/en unknown
-
2001
- 2001-02-28 CN CNA018059236A patent/CN1468224A/en active Pending
- 2001-02-28 PL PL01357874A patent/PL357874A1/en not_active Application Discontinuation
- 2001-02-28 JP JP2001563488A patent/JP2003525274A/en active Pending
- 2001-02-28 BR BR0108816-5A patent/BR0108816A/en not_active Application Discontinuation
- 2001-02-28 MX MXPA02008402A patent/MXPA02008402A/en unknown
- 2001-02-28 HU HU0204458A patent/HUP0204458A3/en unknown
- 2001-02-28 IL IL15109301A patent/IL151093A0/en unknown
- 2001-02-28 EE EEP200200490A patent/EE200200490A/en unknown
- 2001-02-28 CA CA002400657A patent/CA2400657A1/en not_active Abandoned
- 2001-02-28 AU AU2001239331A patent/AU2001239331A1/en not_active Abandoned
- 2001-02-28 RU RU2002125944/04A patent/RU2002125944A/en not_active Application Discontinuation
- 2001-02-28 EP EP01913918A patent/EP1263733A2/en not_active Withdrawn
- 2001-02-28 WO PCT/FI2001/000203 patent/WO2001064645A2/en not_active Application Discontinuation
- 2001-02-28 CZ CZ20022880A patent/CZ20022880A3/en unknown
- 2001-02-28 SK SK1233-2002A patent/SK12332002A3/en unknown
- 2001-02-28 KR KR1020027011453A patent/KR20020089372A/en not_active Application Discontinuation
- 2001-03-01 AR ARP010100993A patent/AR034249A1/en unknown
- 2001-03-01 PE PE2001000208A patent/PE20011084A1/en not_active Application Discontinuation
-
2002
- 2002-08-29 ZA ZA200206956A patent/ZA200206956B/en unknown
- 2002-08-30 NO NO20024159A patent/NO20024159D0/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20020089372A (en) | 2002-11-29 |
SK12332002A3 (en) | 2003-07-01 |
CA2400657A1 (en) | 2001-09-07 |
ZA200206956B (en) | 2003-12-01 |
PE20011084A1 (en) | 2001-10-25 |
EE200200490A (en) | 2003-12-15 |
NO20024159L (en) | 2002-08-30 |
CZ20022880A3 (en) | 2003-06-18 |
FI20000480A0 (en) | 2000-03-01 |
WO2001064645A3 (en) | 2001-12-27 |
EP1263733A2 (en) | 2002-12-11 |
PL357874A1 (en) | 2004-07-26 |
IL151093A0 (en) | 2003-04-10 |
RU2002125944A (en) | 2004-02-27 |
CN1468224A (en) | 2004-01-14 |
WO2001064645A2 (en) | 2001-09-07 |
HUP0204458A3 (en) | 2004-07-28 |
AU2001239331A1 (en) | 2001-09-12 |
BR0108816A (en) | 2002-12-10 |
MXPA02008402A (en) | 2003-10-14 |
JP2003525274A (en) | 2003-08-26 |
HUP0204458A2 (en) | 2003-04-28 |
NO20024159D0 (en) | 2002-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR034249A1 (en) | USE OF QUINOLINE DERIVATIVES AS ALFA-2 ANTAGONISTS; COMPOUNDS DERIVED FROM QUINOLINA AND ITS COMPOSITIONS | |
HUP0301236A2 (en) | Substituted quinazoline derivatives and their use as inhibitors | |
PE20220931A1 (en) | PYRAZOLO[3,4-B]PYRAZINE-TYPE SHP2 PHOSPHATASE INHIBITORS | |
AR037489A1 (en) | REPLACED KINOLINS AND PROCESS FOR PREPARATION | |
AR061815A1 (en) | OXO-PROLINAMIDE COMPOSITE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
AR049711A1 (en) | HETEROCICLIC COMPOUNDS CONDENSED AS INHIBITORS OF ALDOSTERONE SINTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF DISEASES RELATED TO HYPERALDOSTERISM AND EXCESSIVE CORTISO RELEASE | |
AR052943A1 (en) | DERIVATIVES OF 2- (4-OXO-4H-QUINAZOLIN-3-IL) ACETAMIDE | |
AR060658A1 (en) | DICETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | |
AR055878A1 (en) | CYCLOPROPANOCARBOXAMIDE DERIVATIVES | |
AR062074A1 (en) | ALKYLENE 1-PHENYL-2-PYRIDINYL ALCOHOL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | |
PE20080841A1 (en) | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED TO STRESS OR DEPRESSION | |
AR069510A1 (en) | ARILO AND HETEROARILO IMIDAZO [1,5-A] FUSIONED PIRAZINS AS INHIBITORS OF PHOSPHODIESTERASE 10 | |
AR032361A1 (en) | DERIVATIVES OF ANDROSTAN AND SALTS AND SOLVATOS OF THE SAME, ITS USE FOR THE MANUFACTURE OF MEDICINES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS, PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS, AND USEFUL INTERMEDIARIES IN THE PREPARATION OF SUCH COMPOUNDS | |
AR030596A1 (en) | DERIVATIVES OF QUINOLINA AND QUINAZOLINA, A PROCEDURE FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, USE OF THE SAME FOR THE DEVELOPMENT OF MEDICINES | |
AR049696A1 (en) | INDOL DERIVATIVES | |
AR082152A1 (en) | DERIVATIVES OF N- (METILSULFONIL) BENZAMIDE, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF NAV1.7 | |
AR072227A1 (en) | SUBSTITUTED TRIAZINONA DERIVATIVES | |
AR060605A1 (en) | DERIVATIVES OF DIAZEPAN AS ANTAGONISTS OF THE CCR2 RECEIVER | |
AR065531A1 (en) | PIRIMIDINE DERIVATIVES, OBTAINING PROCESSES AND PHARMACEUTICAL COMPOSITIONS. | |
AR051638A1 (en) | PIPERIDINYL COMPOUNDS AND THEIR USE TO TREAT DISORDERS OF BLOCK REPLACEMENT OF TYPE N CALCIUM CHANNELS | |
CY1116183T1 (en) | Piperazinoidions as antagonists of oxytocin receptors | |
AR049346A1 (en) | 3-AMINO-1-ARILPROPIL-INDOLES AS MONOAMINE REABSORTION INHIBITORS | |
AR065811A1 (en) | DERIVATIVES OF 2-AMINO-4H-IMIDAZOL-4-ONA, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS. | |
AR040626A1 (en) | USEFUL QUINOLINE DERIVATIVES AS NEUROPEPTIDE RECEIVER AND (NPY) | |
AR035153A1 (en) | CARBOXAMID DERIVATIVES AND DIHYDROBENZODIOXINE KETONES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |